Orforglipron

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Orforglipron

An oral small-molecule GLP-1 receptor agonist showing 10-11% weight loss in Phase III trials, pending regulatory approval in 2026.

Evidence category: Clinical study. This describes the source category, not approval or certainty.

Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.

Orforglipron (LY3502970) is an oral small-molecule GLP-1 receptor agonist being developed by Eli Lilly for obesity treatment. The ATTAIN-1 Phase III trial enrolled 3,127 adults with obesity over 72 weeks, demonstrating double-digit percentage mean weight loss, with the majority of participants achieving at least a 10% reduction and improvements in cardiometabolic parameters. The ATTAIN-2 trial evaluated orforglipron in adults with obesity or overweight and type 2 diabetes, with all studied amounts meeting primary and key secondary endpoints at 72 weeks. The highest-efficacy regimen, taken once daily without food or water restrictions, lowered weight by a clinically meaningful margin compared with placebo, with meaningful A1C reductions and improved cardiometabolic risk factors. Orforglipron is being developed as an oral medication taken on a daily schedule. With ATTAIN-2 completion, Lilly has the clinical data package required for global regulatory submissions in 2026.

Benefits reported in the imported source

• Phase III trials (ATTAIN-1 and ATTAIN-2) demonstrate 10-11% weight loss
• Meaningful A1C reductions in patients with type 2 diabetes
• Once-daily oral administration without food/water restrictions
• Improvements in cardiometabolic risk factors demonstrated

Risks and limits

• Not yet approved; regulatory submissions expected in 2026
• Gastrointestinal adverse events expected with GLP-1 agonist mechanism
• Long-term safety data beyond 72 weeks not yet available

Source bottom line: Orforglipron is an oral GLP-1 receptor agonist showing 10-11% weight loss in Phase III trials, with regulatory submissions expected in 2026 for obesity and type 2 diabetes indications.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

Pharmacokinetic context

Historical half-life estimate: 51.8–76.1 hours. Ohwaki et al. 2026, J Diabetes Investig, PMID 41325139 — phase 1 ascending-dose study in Japanese participants, week-12 mean terminal half-life Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity
• Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity (availability check 2026-10-15: source not retrieved; HTTP 403)
• Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial (availability check 2026-10-15: source not retrieved; HTTP 403)